Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection

Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection

IntroductionSerum levels of interleukin-6 (IL-6) are increased in COVID-19 patients. IL-6 is an effective therapeutic target in inflammatory diseases and tocilizumab, a monoclonal antibody that blocks signaling via the IL-6 receptor (IL-6R), is used to treat patients with severe COVID-19. However, t...

Full description

Saved in:
Bibliographic Details
Main Authors: Juliane Lokau, Yvonne Garbers, Manuel M. Vicente, Anna Dittrich, Stefan Meltendorf, Holger Lingel, Anja K. Münster-Kühnel, Monika Brunner-Weinzierl, Christoph Garbers
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
interleukin-6
interleukin-6 receptor
gp130
COVID-19
sCD25
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1488745/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1488745/full

Similar Items